Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Flecainide
Drug ID BADD_D00902
Description Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone].[A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.[A186931] It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875]
Indications and Usage Flecainide is is a class Ic antiarrhythmic agent and as such, it is used for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin.
Marketing Status Prescription; Discontinued
ATC Code C01BC04
DrugBank ID DB01195
KEGG ID D07962
MeSH ID D005424
PubChem ID 3356
TTD Drug ID D03DAP
NDC Product Code Not Available
Synonyms Flecainide | Flecainide Acetate | Flecainide Monoacetate | Flecainide Monoacetate, (R)-Isomer | Flecainide Monoacetate, (S)-Isomer | Flecainide, (R)-Isomer | Flecainide, (S)-Isomer | Flecainide, 5-HO-N-(6-oxo)-Derivative | Flecainide, 5-HO-N-(6-oxo)-Derivative, (+-)-Isomer | Flecatab | R818 | Tambocor | Flecadura | Flecainide Monoacetate, (+-)-Isomer | Flecainid-Isis | Flecainid Isis | Flécaïne | Apocard
Chemical Information
Molecular Formula C17H20F6N2O3
CAS Registry Number 54143-55-4
SMILES C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T495269927398; 10810773; 10082151; 10408028
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T397169927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not Available9927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T202519927398; 10810773; 10082151; 10408028
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Torsade de pointes02.03.04.0050.002637%Not Available
Tremor17.01.06.0020.001318%
Unresponsive to stimuli17.02.05.0310.002637%Not Available
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.0100.004614%
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred17.17.01.010; 06.02.06.0070.001318%
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Tachyarrhythmia02.03.02.0080.001318%Not Available
Balance disorder17.02.02.007--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Pulseless electrical activity02.03.04.0200.000688%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Urinary tract obstruction20.08.01.004--
Blood disorder01.05.01.004--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.001318%Not Available
Acute kidney injury20.01.03.0160.003296%
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.007--Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000344%
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Coeliac disease10.04.04.012; 07.17.01.008; 14.02.01.0070.001318%Not Available
The 6th Page    First    Pre   6    Total 6 Pages